ArticleJournal of clinical apheresis2025
Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus Criteria.
Article in Journal of clinical apheresis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus Criteria.Journal of clinical apheresis · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Chronic graft-versus-host disease (cGVHD) remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Many cGVHD patients require prolonged systemic immunosuppression with corticosteroids, which carry significant adverse effects, and alternative therapies are often required. Extracorporeal photopheresis (ECP) has historically shown promise as a cGVHD treatment, but recent efficacy data have been limited and inconsistent. To evaluate the efficacy of ECP as a treatment for cGVHD patients according to the 2014 NIH Consensus Criteria. We retrospectively analyzed 53 patients treated with ECP for cGVHD at our center from 2010 to 2024. ORR was 51%, with 3 CRs (5.7%) and 24 PRs (45.3%). Highest organ-specific responses were seen in the gastrointestinal tract (70%) and liver (69.2%), and lowest in joints/fascia (15.4%) and lung (21.4%). A total of 23 (43.4%) patients experienced at least one treatment-related complication (TRC), with a median time to first TRC of 29.3 weeks (IQR = 7.4-55.2). The estimated 1- and 3-year OS was 79.2% (95% CI = 65.7%-87.9%) and 70.1% (95% CI = 55.0%-80.9%), respectively. The estimated 1- and 3-year FFS was 75.5% (95% CI = 61.5%-84.9%) and 43.1% (95% CI = 28.6%-56.9%), respectively. Of the 37 patients who were on corticosteroids at the start of ECP, 22 (59.5%) were able to decrease their daily dose by ≥ 50% by the time of ECP discontinuation. Multivariable analyses revealed that patients on tacrolimus and other non-steroid immunosuppressive treatments (ISTs) had better outcomes in clinical benefit, steroid-sparing, overall survival, and failure-free survival. ECP was a safe and effective treatment for cGVHD in our population and showed promising efficacy when used in combination with tacrolimus or other ISTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.